Incyte to Develop MacroGenics’ Cancer Immunotherapy MGA012 in Up-to-$900M+ Collab – Genetic Engineering & Biotechnology News
|
Incyte to Develop MacroGenics' Cancer Immunotherapy MGA012 in Up-to-$900M+ Collab
Genetic Engineering & Biotechnology News Incyte will partner with MacroGenics to develop its Phase I cancer immunotherapy candidate MGA012, a monoclonal antibody designed to inhibit programmed cell death protein 1 (PD-1), through a collaboration that could generate up to $900 million-plus for … |
